首页 > 最新文献

Genes, Chromosomes & Cancer最新文献

英文 中文
Susanne M. Gollin, PhD, Sept 22, 1953–April 6, 2025 Susanne M. Gollin,博士,1953年9月22日- 2025年4月6日
IF 2.8 2区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-08-12 DOI: 10.1002/gcc.70067
Jeremy M. Berg, Christa Lese Martin, Wendie A. Berg, Shalini C. Reshmi
{"title":"Susanne M. Gollin, PhD, Sept 22, 1953–April 6, 2025","authors":"Jeremy M. Berg, Christa Lese Martin, Wendie A. Berg, Shalini C. Reshmi","doi":"10.1002/gcc.70067","DOIUrl":"https://doi.org/10.1002/gcc.70067","url":null,"abstract":"","PeriodicalId":12700,"journal":{"name":"Genes, Chromosomes & Cancer","volume":"64 8","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144814609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CD34-Positive Acral Chondromyxoid Mesenchymal Neoplasm Harboring a Novel TCF4::ERG Fusion cd34阳性的肢端软骨粘液样间充质肿瘤含有一种新的TCF4::ERG融合
IF 2.8 2区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-08-12 DOI: 10.1002/gcc.70073
Eric C. Honaker, Laura M. Warmke, Ameline Baptiste, Daniel Baumhoer, Esther Baranov, Eitan Halper-Stromberg, Carina A. Dehner

Molecular testing has significantly transformed the field of anatomic pathology over the past several decades. Despite these advances, acral mesenchymal neoplasms remain diagnostically challenging, requiring careful integration of clinical presentation, histologic features, and molecular findings for accurate classification. Herein, we present a case of an acral chondromyxoid mesenchymal neoplasm harboring a novel in-frame TCF4::ERG fusion involving the right index finger of a 26-year-old female. Morphologically, this tumor consisted of nests and sheets of monotonous small round-to-ovoid cells embedded in a background of chondromyxoid stroma and hyalinized collagen. The tumor cells were diffusely CD34, ERG, and focally p63 reactive, while S100 protein, cytokeratin AE1/AE3, Pan-TRK, ALK, smooth muscle actin, and desmin were negative. Albeit short follow-up (3 months), the patient continues to do well without evidence of metastasis or local recurrence.

在过去的几十年里,分子检测极大地改变了解剖病理学领域。尽管取得了这些进展,肢端间充质肿瘤的诊断仍然具有挑战性,需要仔细结合临床表现、组织学特征和分子发现进行准确分类。在此,我们报告一例涉及26岁女性右手食指的肢端软骨黏液样间充质肿瘤伴新型框架内TCF4::ERG融合。形态学上,该肿瘤由嵌在软骨粘液样基质和透明胶原背景中的巢状和单调的小圆形到卵形细胞片组成。肿瘤细胞弥漫性CD34、ERG、局灶性p63阳性,S100蛋白、细胞角蛋白AE1/AE3、Pan-TRK、ALK、平滑肌肌动蛋白、desmin阴性。虽然随访时间较短(3个月),但患者情况良好,无转移或局部复发迹象。
{"title":"CD34-Positive Acral Chondromyxoid Mesenchymal Neoplasm Harboring a Novel TCF4::ERG Fusion","authors":"Eric C. Honaker,&nbsp;Laura M. Warmke,&nbsp;Ameline Baptiste,&nbsp;Daniel Baumhoer,&nbsp;Esther Baranov,&nbsp;Eitan Halper-Stromberg,&nbsp;Carina A. Dehner","doi":"10.1002/gcc.70073","DOIUrl":"https://doi.org/10.1002/gcc.70073","url":null,"abstract":"<p>Molecular testing has significantly transformed the field of anatomic pathology over the past several decades. Despite these advances, acral mesenchymal neoplasms remain diagnostically challenging, requiring careful integration of clinical presentation, histologic features, and molecular findings for accurate classification. Herein, we present a case of an acral chondromyxoid mesenchymal neoplasm harboring a novel in-frame <i>TCF4::ERG</i> fusion involving the right index finger of a 26-year-old female. Morphologically, this tumor consisted of nests and sheets of monotonous small round-to-ovoid cells embedded in a background of chondromyxoid stroma and hyalinized collagen. The tumor cells were diffusely CD34, ERG, and focally p63 reactive, while S100 protein, cytokeratin AE1/AE3, Pan-TRK, ALK, smooth muscle actin, and desmin were negative. Albeit short follow-up (3 months), the patient continues to do well without evidence of metastasis or local recurrence.</p>","PeriodicalId":12700,"journal":{"name":"Genes, Chromosomes & Cancer","volume":"64 8","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/gcc.70073","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144814893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Macroscopic Monozygotic Androgenetic/Biparental Mosaicism: Molecular Characterization and Clinical Implications 宏观单合子雄激素/双亲嵌合体:分子表征和临床意义
IF 2.8 2区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-08-12 DOI: 10.1002/gcc.70078
H. Usui, N. Nakamura, E. Katayama, A. Sato, T. Mukouyama, N. Sakai, S. Otsuka, R. Okuya, Y. Habu, K. Nishikimi, S. Tate, J. Ikeda, K. Koga

Hydatidiform moles represent abnormal pregnancies characterized by trophoblastic hyperproliferation. However, accurate diagnosis of partial hydatidiform moles (PHM) remains challenging. We present a rare case of a monozygotic androgenetic/biparental mosaic in a 26-year-old primigravida. The patient was referred to our institution for a suspected PHM, and ultrasonography revealed a nonviable embryo-like structure alongside villous formations with focal cystic changes. Pathological examination of the evacuated tissue revealed the coexistence of normal and hydropic villi. Histological assessment with p57KIP2 immunohistochemistry initially suggested PHM; however, some cytotrophoblasts and villous stromal cells were negative for p57KIP2 immunoreactivity. Therefore, we conducted short tandem repeat analysis separately for normal villous tissue and cystic villous lesions to elucidate the genetic origin of this unusual presentation. The normal villous portion exhibited biparental diploidy, whereas the cystic villous portion exhibited androgenetic monospermic patterns. Comparisons across all 16 loci revealed concordance between the paternal alleles of biparental diploid villi and the androgenic molar alleles, indicating a single sperm origin. SNP array analysis with B allele frequency plotting confirmed these findings at the whole-genome level; normal villi showed biparental diploid patterns, whereas cystic villi displayed uniparental disomic patterns. These results demonstrate that both components originated from a monozygotic conception rather than from dizygotic twinning. Therefore, we propose a clinical category based on the sequelae of endoduplication and the formation of a tripolar spindle apparatus through the first meiotic division, encompassing macroscopic androgenetic/biparental mosaicism, twin pregnancy with a hydatidiform mole, microscopic androgenetic/biparental mosaicism, and confined placental mosaicism. Given the presence of androgenetic elements and our institutional experience with gestational trophoblastic neoplasia development in a similar case, we recommend that such cases be managed according to complete hydatidiform mole surveillance protocols. This case highlights the diagnostic challenges posed by monozygotic androgenetic/biparental mosaic mechanisms and emphasizes the importance of molecular genetic analysis for the accurate diagnosis and appropriate clinical management of atypical hydatidiform moles.

葡萄胎代表以滋养细胞增生为特征的异常妊娠。然而,准确诊断部分葡萄胎(PHM)仍然具有挑战性。我们报告一例罕见的单合子雄激素/双亲嵌合在一个26岁的原鸟。患者因疑似PHM而被转介到我们的机构,超声检查显示不可存活的胚胎样结构以及绒毛形成和局灶性囊性改变。病理检查显示正常绒毛和水绒毛共存。p57KIP2免疫组化初步提示PHM;而部分细胞滋养层细胞和绒毛间质细胞p57KIP2免疫反应性为阴性。因此,我们分别对正常绒毛组织和囊性绒毛病变进行了短串联重复分析,以阐明这种不寻常表现的遗传起源。正常绒毛部分表现为双亲本二倍体,而囊性绒毛部分表现为雄激素单精子模式。所有16个位点的比较结果显示,双亲本二倍体绒毛父本等位基因与雄激素磨牙等位基因一致,表明精子来源单一。SNP阵列分析与B等位基因频率图在全基因组水平上证实了这些发现;正常绒毛表现为双亲二倍体,而囊绒毛表现为双亲二体。这些结果表明,这两种成分都来自同卵受精,而不是异卵双胞胎。因此,我们提出了一个基于内复制和通过第一次减数分裂形成三极纺锤体的后果的临床分类,包括宏观的雄激素发生/双亲嵌合体,双胎妊娠伴有包子状痣,微观的雄激素发生/双亲嵌合体和限制性胎盘嵌合体。鉴于雄激素因素的存在和我们在类似病例中妊娠滋养细胞瘤发展的机构经验,我们建议根据完整的葡萄胎监测方案来处理此类病例。本病例强调了单合子雄激素/双亲本嵌合机制所带来的诊断挑战,并强调了分子遗传学分析对非典型包虫体痣的准确诊断和适当临床管理的重要性。
{"title":"Macroscopic Monozygotic Androgenetic/Biparental Mosaicism: Molecular Characterization and Clinical Implications","authors":"H. Usui,&nbsp;N. Nakamura,&nbsp;E. Katayama,&nbsp;A. Sato,&nbsp;T. Mukouyama,&nbsp;N. Sakai,&nbsp;S. Otsuka,&nbsp;R. Okuya,&nbsp;Y. Habu,&nbsp;K. Nishikimi,&nbsp;S. Tate,&nbsp;J. Ikeda,&nbsp;K. Koga","doi":"10.1002/gcc.70078","DOIUrl":"https://doi.org/10.1002/gcc.70078","url":null,"abstract":"<div>\u0000 \u0000 <p>Hydatidiform moles represent abnormal pregnancies characterized by trophoblastic hyperproliferation. However, accurate diagnosis of partial hydatidiform moles (PHM) remains challenging. We present a rare case of a monozygotic androgenetic/biparental mosaic in a 26-year-old primigravida. The patient was referred to our institution for a suspected PHM, and ultrasonography revealed a nonviable embryo-like structure alongside villous formations with focal cystic changes. Pathological examination of the evacuated tissue revealed the coexistence of normal and hydropic villi. Histological assessment with p57KIP2 immunohistochemistry initially suggested PHM; however, some cytotrophoblasts and villous stromal cells were negative for p57KIP2 immunoreactivity. Therefore, we conducted short tandem repeat analysis separately for normal villous tissue and cystic villous lesions to elucidate the genetic origin of this unusual presentation. The normal villous portion exhibited biparental diploidy, whereas the cystic villous portion exhibited androgenetic monospermic patterns. Comparisons across all 16 loci revealed concordance between the paternal alleles of biparental diploid villi and the androgenic molar alleles, indicating a single sperm origin. SNP array analysis with B allele frequency plotting confirmed these findings at the whole-genome level; normal villi showed biparental diploid patterns, whereas cystic villi displayed uniparental disomic patterns. These results demonstrate that both components originated from a monozygotic conception rather than from dizygotic twinning. Therefore, we propose a clinical category based on the sequelae of endoduplication and the formation of a tripolar spindle apparatus through the first meiotic division, encompassing macroscopic androgenetic/biparental mosaicism, twin pregnancy with a hydatidiform mole, microscopic androgenetic/biparental mosaicism, and confined placental mosaicism. Given the presence of androgenetic elements and our institutional experience with gestational trophoblastic neoplasia development in a similar case, we recommend that such cases be managed according to complete hydatidiform mole surveillance protocols. This case highlights the diagnostic challenges posed by monozygotic androgenetic/biparental mosaic mechanisms and emphasizes the importance of molecular genetic analysis for the accurate diagnosis and appropriate clinical management of atypical hydatidiform moles.</p>\u0000 </div>","PeriodicalId":12700,"journal":{"name":"Genes, Chromosomes & Cancer","volume":"64 8","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144814892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Type B3 Thymoma With a Novel KMT2A::MAML3 Fusion: Expanding the Spectrum of Gene Fusions Beyond the MAML2 Gene 具有新的KMT2A::MAML3融合的B3型胸腺瘤:扩展了MAML2基因以外的基因融合谱
IF 2.8 2区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-08-11 DOI: 10.1002/gcc.70071
Ziqi Zhou, Yanqi Yu, Conghao Chen, Jie Lin

Mastermind-like transcriptional coactivator (MAML) gene fusions have been documented in Thymic Epithelial Tumors (TETs). Specifically, lysine methyltransferase 2A (KMT2A)::MAML2 gene fusions are associated with type B2 and B3 thymomas. Here, we report for the first time a young patient with invasive type B3 thymoma harboring a novel KMT2A::MAML3 gene fusion. MAML3 and MAML2 are paralogues. In addition to the classic type B3 thymoma histology, this article documents intratumor heterogeneity, characterized by a trabecular and fascicular pattern, as well as areas of clear cells. Immunohistochemistry showed keratin positivity in tumor cells, while neuroendocrine markers were negative in trabecular regions. DNA-based next-generation sequencing failed to identify pathogenic variants, but RNA sequencing detected the KMT2A::MAML3 gene fusion. We compared the gene fusion sites of MAML2 and MAML3, focusing on exon 2, and found that they share similar functional protein domains. Moreover, the same domain appeared downstream of the KMT2A::MAML2 fusion protein. Therefore, we hypothesize that MAML3 gene fusions, like MAML2, lead to abnormal Notch signaling pathways and increase the invasive potential of certain thymoma subtypes. Our findings expand the genetic landscape of aggressive thymomas and offer new insights for molecular studies in TETs.

脑主脑样转录共激活因子(MAML)基因融合已在胸腺上皮肿瘤(TETs)中得到证实。具体来说,赖氨酸甲基转移酶2A (KMT2A)::MAML2基因融合与B2型和B3型胸腺瘤相关。在这里,我们首次报道了一例浸润性B3型胸腺瘤的年轻患者,该患者携带一种新的KMT2A::MAML3基因融合。MAML3和MAML2是平行的。除了典型的B3型胸腺瘤组织学外,本文还记录了肿瘤内的异质性,其特征是小梁型和束状型,以及透明细胞区。免疫组化显示肿瘤细胞角蛋白阳性,小梁区神经内分泌标志物阴性。基于dna的新一代测序未能确定致病变异,但RNA测序检测到KMT2A::MAML3基因融合。我们比较了MAML2和MAML3的基因融合位点,重点关注外显子2,发现它们具有相似的功能蛋白结构域。此外,相同的结构域出现在KMT2A::MAML2融合蛋白的下游。因此,我们假设MAML3基因融合与MAML2一样,导致Notch信号通路异常,并增加某些胸腺瘤亚型的侵袭潜力。我们的发现扩大了侵袭性胸腺瘤的遗传格局,并为tet的分子研究提供了新的见解。
{"title":"Type B3 Thymoma With a Novel KMT2A::MAML3 Fusion: Expanding the Spectrum of Gene Fusions Beyond the MAML2 Gene","authors":"Ziqi Zhou,&nbsp;Yanqi Yu,&nbsp;Conghao Chen,&nbsp;Jie Lin","doi":"10.1002/gcc.70071","DOIUrl":"https://doi.org/10.1002/gcc.70071","url":null,"abstract":"<div>\u0000 \u0000 <p>Mastermind-like transcriptional coactivator (<i>MAML</i>) gene fusions have been documented in Thymic Epithelial Tumors (TETs). Specifically, lysine methyltransferase 2A (<i>KMT2A)::MAML2</i> gene fusions are associated with type B2 and B3 thymomas. Here, we report for the first time a young patient with invasive type B3 thymoma harboring a novel <i>KMT2A::MAML3</i> gene fusion. <i>MAML3</i> and <i>MAML2</i> are paralogues. In addition to the classic type B3 thymoma histology, this article documents intratumor heterogeneity, characterized by a trabecular and fascicular pattern, as well as areas of clear cells. Immunohistochemistry showed keratin positivity in tumor cells, while neuroendocrine markers were negative in trabecular regions. DNA-based next-generation sequencing failed to identify pathogenic variants, but RNA sequencing detected the <i>KMT2A::MAML3</i> gene fusion. We compared the gene fusion sites of <i>MAML2</i> and <i>MAML3</i>, focusing on exon 2, and found that they share similar functional protein domains. Moreover, the same domain appeared downstream of the <i>KMT2A::MAML2</i> fusion protein. Therefore, we hypothesize that <i>MAML3</i> gene fusions, like <i>MAML2</i>, lead to abnormal Notch signaling pathways and increase the invasive potential of certain thymoma subtypes. Our findings expand the genetic landscape of aggressive thymomas and offer new insights for molecular studies in TETs.</p>\u0000 </div>","PeriodicalId":12700,"journal":{"name":"Genes, Chromosomes & Cancer","volume":"64 8","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144814781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Widening the Spectrum of Fusion Events in Schwannoma: Identification of a Novel TANC1::HTRA1 Fusion. 扩大神经鞘瘤中融合事件的频谱:一种新的TANC1::HTRA1融合的鉴定。
IF 2.8 2区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-08-01 DOI: 10.1002/gcc.70072
James A Watkins, Patrick Tarpey, Maria O'Donovan, John A Tadross, Nadia Mohammed

A range of genomic drivers have been identified in schwannomas, including a number of translocations, most commonly SH3PXD2A::HTRA1. To date, despite the analysis of large numbers of cases, no examples of variant HTRA1 partners have been described. We describe a schwannoma arising in the periportal region in which a novel TANC1::HTRA1 fusion was identified. The identification of this variant expands the range of fusion drivers in schwannoma and offers insight into the pathogenic mechanism of HTRA1 fusions and their utility in molecular diagnosis.

在神经鞘瘤中已经发现了一系列基因组驱动因素,包括许多易位,最常见的是SH3PXD2A::HTRA1。迄今为止,尽管对大量病例进行了分析,但没有描述变异HTRA1伴侣的例子。我们描述了在门静脉周围区域出现的神经鞘瘤,其中发现了一种新的TANC1::HTRA1融合。该变异的发现扩大了神经鞘瘤中融合驱动因子的范围,并为HTRA1融合的致病机制及其在分子诊断中的应用提供了新的见解。
{"title":"Widening the Spectrum of Fusion Events in Schwannoma: Identification of a Novel TANC1::HTRA1 Fusion.","authors":"James A Watkins, Patrick Tarpey, Maria O'Donovan, John A Tadross, Nadia Mohammed","doi":"10.1002/gcc.70072","DOIUrl":"10.1002/gcc.70072","url":null,"abstract":"<p><p>A range of genomic drivers have been identified in schwannomas, including a number of translocations, most commonly SH3PXD2A::HTRA1. To date, despite the analysis of large numbers of cases, no examples of variant HTRA1 partners have been described. We describe a schwannoma arising in the periportal region in which a novel TANC1::HTRA1 fusion was identified. The identification of this variant expands the range of fusion drivers in schwannoma and offers insight into the pathogenic mechanism of HTRA1 fusions and their utility in molecular diagnosis.</p>","PeriodicalId":12700,"journal":{"name":"Genes, Chromosomes & Cancer","volume":"64 8","pages":"e70072"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative DNA Methylation Profiling of Human and Murine ALK-Positive B-Cell Neoplasms 人和小鼠alk阳性b细胞肿瘤DNA甲基化谱的比较
IF 3.1 2区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-07-26 DOI: 10.1002/gcc.70060
Selina Glaser, Rabea Wagener, Shannon K. Harkins, Claudia Voena, Susanne Bens, Wolfram Klapper, Camille Laurent, Stephan Mathas, Meiqi Ren, Sandrine Sander, Charlotte Schnaudt-Mastrangelo, Wilhelm Wößmann, Luc Xerri, Ole Ammerpohl, Andrew D. Zelenetz, Abner Louissaint Jr, Roberto Chiarle, Reiner Siebert

Structural genomic variants leading to anaplastic lymphoma kinase (ALK) gene fusions and aberrant expression of the ALK tyrosine kinase are the hallmark of subtypes of T- and B-lineage neoplasms, namely ALK-positive anaplastic large lymphoma (ALCL) and ALK-positive large B-cell lymphoma (LBCL). The latter is a rare aggressive lymphoma, which has been initially identified as a variant of diffuse LBCL (DLBCL) with plasmablastic features. Here, we performed comparative DNA methylation profiling of human and murine ALK-positive B-cell neoplasms. Array-based DNA methylation data from ALK-positive LBCL samples of eight patients were compared to that of DLBCL (n = 75), multiple myeloma (MM, n = 24), ALK-positive ALCL (n = 12) and normal B-cell populations (n = 93). ALK-positive LBCLs share a distinct DNA methylation signature similar to that of MM, characterized by lower global DNA methylation levels compared to DLBCLs and normal B-cell populations. DNA methylation alterations in ALK-positive LBCL were predominantly located in heterochromatic and polycomb-repressed regions. The epigenetic age and relative proliferative history of ALK-positive LBCL were intermediate between MM and DLBCL. B-cell neoplasms in NPM::ALK transgenic mice showed a similar hypomethylated signature when compared to normal murine B cells. Cross-species comparison indicated conservation of chromatin states and pathways affected by hypomethylation. Together, the findings suggest that in line with their phenotypical appearance human and murine ALK-positive B-cell lymphomas share an epigenetic profile more closely resembling that of plasma cell neoplasias than that of DLBCLs.

导致间变性淋巴瘤激酶(ALK)基因融合和ALK酪氨酸激酶异常表达的结构基因组变异是T和b谱系肿瘤亚型的标志,即ALK阳性间变性大淋巴瘤(ALCL)和ALK阳性大b细胞淋巴瘤(LBCL)。后者是一种罕见的侵袭性淋巴瘤,最初被确定为具有浆母细胞特征的弥漫性LBCL (DLBCL)的一种变体。在这里,我们对人和小鼠alk阳性b细胞肿瘤进行了比较DNA甲基化谱分析。将8例alk阳性LBCL患者的DNA甲基化数据与DLBCL (n = 75)、多发性骨髓瘤(MM, n = 24)、alk阳性ALCL (n = 12)和正常b细胞群体(n = 93)的DNA甲基化数据进行比较。alk阳性lbcl具有与MM相似的独特DNA甲基化特征,与dlbcl和正常b细胞群体相比,其特征是整体DNA甲基化水平较低。alk阳性LBCL的DNA甲基化改变主要位于异色区和polycomb抑制区。alk阳性LBCL的表观遗传年龄和相对增殖史介于MM和DLBCL之间。与正常小鼠B细胞相比,NPM::ALK转基因小鼠的B细胞肿瘤表现出类似的低甲基化特征。跨物种比较表明,染色质状态的保护和受低甲基化影响的途径。总之,研究结果表明,与他们的表型外观一致,人类和小鼠alk阳性b细胞淋巴瘤的表观遗传特征更接近于浆细胞瘤,而不是dlbcl。
{"title":"Comparative DNA Methylation Profiling of Human and Murine ALK-Positive B-Cell Neoplasms","authors":"Selina Glaser,&nbsp;Rabea Wagener,&nbsp;Shannon K. Harkins,&nbsp;Claudia Voena,&nbsp;Susanne Bens,&nbsp;Wolfram Klapper,&nbsp;Camille Laurent,&nbsp;Stephan Mathas,&nbsp;Meiqi Ren,&nbsp;Sandrine Sander,&nbsp;Charlotte Schnaudt-Mastrangelo,&nbsp;Wilhelm Wößmann,&nbsp;Luc Xerri,&nbsp;Ole Ammerpohl,&nbsp;Andrew D. Zelenetz,&nbsp;Abner Louissaint Jr,&nbsp;Roberto Chiarle,&nbsp;Reiner Siebert","doi":"10.1002/gcc.70060","DOIUrl":"https://doi.org/10.1002/gcc.70060","url":null,"abstract":"<p>Structural genomic variants leading to anaplastic lymphoma kinase (ALK) gene fusions and aberrant expression of the ALK tyrosine kinase are the hallmark of subtypes of T- and B-lineage neoplasms, namely ALK-positive anaplastic large lymphoma (ALCL) and ALK-positive large B-cell lymphoma (LBCL). The latter is a rare aggressive lymphoma, which has been initially identified as a variant of diffuse LBCL (DLBCL) with plasmablastic features. Here, we performed comparative DNA methylation profiling of human and murine ALK-positive B-cell neoplasms. Array-based DNA methylation data from ALK-positive LBCL samples of eight patients were compared to that of DLBCL (<i>n</i> = 75), multiple myeloma (MM, <i>n</i> = 24), ALK-positive ALCL (<i>n</i> = 12) and normal B-cell populations (<i>n</i> = 93). ALK-positive LBCLs share a distinct DNA methylation signature similar to that of MM, characterized by lower global DNA methylation levels compared to DLBCLs and normal B-cell populations. DNA methylation alterations in ALK-positive LBCL were predominantly located in heterochromatic and polycomb-repressed regions. The epigenetic age and relative proliferative history of ALK-positive LBCL were intermediate between MM and DLBCL. B-cell neoplasms in <i>NPM</i>::<i>ALK</i> transgenic mice showed a similar hypomethylated signature when compared to normal murine B cells. Cross-species comparison indicated conservation of chromatin states and pathways affected by hypomethylation. Together, the findings suggest that in line with their phenotypical appearance human and murine ALK-positive B-cell lymphomas share an epigenetic profile more closely resembling that of plasma cell neoplasias than that of DLBCLs.</p>","PeriodicalId":12700,"journal":{"name":"Genes, Chromosomes & Cancer","volume":"64 7","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/gcc.70060","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144705293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tr-KIT Downstream Regulation by YY1 and NFYA Transcription Factors Knockdown in Prostate Cancer Cells 前列腺癌细胞中YY1和NFYA转录因子下调对Tr-KIT的下游调控
IF 3.1 2区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-07-26 DOI: 10.1002/gcc.70063
Sercan Ergun, Ferda Arı, Erdal Benli, Diler Us Altay, Tevfik Noyan, Havva Erdem, Yeliz Kaşko Arıcı, Oğuzhan Akgün, Senanur Aslan

Background

Prostate cancer is a common and deadly cancer among men and has been the subject of many patients in its diagnosis and treatment. Imatinib, a tyrosine kinase inhibitor, can slow tumor formation by targeting c-KIT, an oncogenic receptor tyrosine kinase protein over-expressed in PCa cases. However, Imatinib has no effect on tr-KIT, a truncated form of c-KIT, which is over-expressed in PCa and is associated with neoplastic transformation. In this study, it is aimed to answer whether the anti-proliferative efficacy of Imatinib on PCa cells could be enhanced by inhibition of tr-KIT specific transcription factors.

Methods and Results

For this purpose, gene expression analysis and cell viability assays were performed in LNCaP prostate cancer cells to investigate the effects of inhibition of transcription factors controlling tr-KIT expression (YY1 and NFYA) in combination with Imatinib administration. As a result, YY1 and NFYA were identified as tr-KIT-specific transcription factors and found that their knockdown increased the effectiveness of Imatinib mesylate treatment on LNCaP cells. The study also analyzed the gene expression changes of c-KIT, FYN, PLCγ1, and SAM68 genes and found that SAM68 expression decreased with NFYA and YY1 knockdown, suggesting the existence of other unknown mediators in the tr-KIT pathway.

Conclusions

All in all, this study demonstrates that tr-KIT may be a potential pharmacological target for prostate cancer treatment and that inhibition of the transcription factors YY1 and NFYA may enhance the efficacy of Imatinib. SAM68 was found to be the most affected protein by the treatments, guiding future research.

前列腺癌是男性中一种常见的致命癌症,一直是许多患者诊断和治疗的主题。伊马替尼是一种酪氨酸激酶抑制剂,可以通过靶向c-KIT来减缓肿瘤的形成,c-KIT是一种致癌受体酪氨酸激酶蛋白,在PCa病例中过度表达。然而,伊马替尼对tr-KIT没有影响,tr-KIT是c-KIT的一种截断形式,在PCa中过表达,与肿瘤转化有关。本研究旨在回答伊马替尼对PCa细胞的抗增殖作用是否可以通过抑制tr-KIT特异性转录因子而增强。方法与结果为此,我们对LNCaP前列腺癌细胞进行基因表达分析和细胞活力测定,探讨伊马替尼联合给药抑制tr-KIT表达的转录因子(YY1和NFYA)的影响。因此,YY1和NFYA被鉴定为tr- kit特异性转录因子,并发现它们的敲低增加了甲磺酸伊马替尼治疗LNCaP细胞的有效性。本研究还分析了c-KIT、FYN、plc - γ1和SAM68基因的基因表达变化,发现SAM68的表达随着NFYA和YY1的敲低而降低,提示在tr-KIT通路中存在其他未知的介质。综上所述,本研究表明tr-KIT可能是治疗前列腺癌的潜在药理靶点,抑制转录因子YY1和NFYA可能会增强伊马替尼的疗效。SAM68是受这些处理影响最大的蛋白,对今后的研究具有指导意义。
{"title":"Tr-KIT Downstream Regulation by YY1 and NFYA Transcription Factors Knockdown in Prostate Cancer Cells","authors":"Sercan Ergun,&nbsp;Ferda Arı,&nbsp;Erdal Benli,&nbsp;Diler Us Altay,&nbsp;Tevfik Noyan,&nbsp;Havva Erdem,&nbsp;Yeliz Kaşko Arıcı,&nbsp;Oğuzhan Akgün,&nbsp;Senanur Aslan","doi":"10.1002/gcc.70063","DOIUrl":"https://doi.org/10.1002/gcc.70063","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Prostate cancer is a common and deadly cancer among men and has been the subject of many patients in its diagnosis and treatment. Imatinib, a tyrosine kinase inhibitor, can slow tumor formation by targeting c-KIT, an oncogenic receptor tyrosine kinase protein over-expressed in PCa cases. However, Imatinib has no effect on tr-KIT, a truncated form of c-KIT, which is over-expressed in PCa and is associated with neoplastic transformation. In this study, it is aimed to answer whether the anti-proliferative efficacy of Imatinib on PCa cells could be enhanced by inhibition of tr-KIT specific transcription factors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>For this purpose, gene expression analysis and cell viability assays were performed in LNCaP prostate cancer cells to investigate the effects of inhibition of transcription factors controlling tr-KIT expression (YY1 and NFYA) in combination with Imatinib administration. As a result, YY1 and NFYA were identified as tr-KIT-specific transcription factors and found that their knockdown increased the effectiveness of Imatinib mesylate treatment on LNCaP cells. The study also analyzed the gene expression changes of c-KIT, FYN, PLCγ1, and SAM68 genes and found that SAM68 expression decreased with NFYA and YY1 knockdown, suggesting the existence of other unknown mediators in the tr-KIT pathway.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>All in all, this study demonstrates that tr-KIT may be a potential pharmacological target for prostate cancer treatment and that inhibition of the transcription factors YY1 and NFYA may enhance the efficacy of Imatinib. SAM68 was found to be the most affected protein by the treatments, guiding future research.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12700,"journal":{"name":"Genes, Chromosomes & Cancer","volume":"64 7","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144705688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular Classification of Resected Primary Duodenal Adenocarcinoma 原发性十二指肠腺癌切除术的分子分型
IF 3.1 2区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-07-11 DOI: 10.1002/gcc.70061
Jacob de Bakker, Hedde Biesma, Tanya Soeratram, Jacqueline Egthuijsen, Tim de Back, Marc Besselink, Louis Vermeulen, Bauke Ylstra, Nicole van Grieken, Geert Kazemier

Introduction

The molecular and histological characteristics of primary duodenal adenocarcinoma (DA) have been poorly described, which hampers the development of new treatment options. This study aimed to characterize the landscape of chromosomal copy number aberrations (CNAs), microsatellite instability status, and tumor–stroma content, and their association with clinicopathological characteristics of patients with DA.

Methods

DNA was extracted from tumor tissues of patients who underwent a primary surgical resection for DA in a single center (2000–2019). Shallow whole genome sequencing (sWGS) was performed to identify chromosomal CNAs and the genomic instability index (GII), for which 25% of the genome was altered, was used to classify tumors as CNAlow or CNAhigh. A PCR-based assay was performed to classify tumors as microsatellite stable (MSS) or instable (MSI). Immunohistochemistry and digital image analysis were performed to determine the tumor–stroma content, for which 50% stroma content was used to classify tumors as stromalow or stromahigh.

Results

Among 74 patients with resected DA, sWGS identified 39 (52.7%) CNAlow and 35 (47.3%) CNAhigh tumors. Overall, 16 (21.6%) DAs were MSI. All MSI tumors were CNAlow. The tumor–stroma content was low in 51 (68.9%) and high in 23 (31.1%) of DAs. CNA status was most predictive for 5-year overall survival: 45.5% for patients with CNAlow compared to 31.0% for patients with CNAhigh DA (HR 2.20, 95% CI 1.12–4.30, p = 0.02).

Conclusion

About half of resected DAs had CNAlow, which was associated with the most favorable prognosis. Subgrouping of DA could be used for patient stratification in future trials testing novel therapies.

对原发性十二指肠腺癌(DA)的分子和组织学特征描述甚少,这阻碍了新的治疗选择的发展。本研究旨在描述染色体拷贝数畸变(CNAs)、微卫星不稳定状态和肿瘤基质含量的特征,以及它们与DA患者临床病理特征的关系。方法从单中心(2000-2019年)接受原发性DA手术切除的患者肿瘤组织中提取DNA。浅全基因组测序(sWGS)用于鉴定染色体CNAs,基因组不稳定性指数(GII)用于将肿瘤分类为CNAlow或CNAhigh,其中25%的基因组发生了改变。采用pcr法将肿瘤分为微卫星稳定型(MSS)和不稳定型(MSI)。通过免疫组化和数字图像分析确定肿瘤间质含量,其中间质含量为50%的肿瘤分为stromalow或stromahigh。结果74例DA切除患者中,sWGS检出39例(52.7%)CNAlow肿瘤,35例(47.3%)CNAhigh肿瘤。总的来说,16个da(21.6%)是MSI。所有MSI肿瘤均为cnlow。肿瘤间质含量低51例(68.9%),高23例(31.1%)。CNA状态最能预测5年总生存率:cnlow患者为45.5%,而cna高DA患者为31.0% (HR 2.20, 95% CI 1.12-4.30, p = 0.02)。结论约一半的切除DAs存在CNAlow,其预后较好。DA的亚组可用于未来试验新疗法的患者分层。
{"title":"Molecular Classification of Resected Primary Duodenal Adenocarcinoma","authors":"Jacob de Bakker,&nbsp;Hedde Biesma,&nbsp;Tanya Soeratram,&nbsp;Jacqueline Egthuijsen,&nbsp;Tim de Back,&nbsp;Marc Besselink,&nbsp;Louis Vermeulen,&nbsp;Bauke Ylstra,&nbsp;Nicole van Grieken,&nbsp;Geert Kazemier","doi":"10.1002/gcc.70061","DOIUrl":"https://doi.org/10.1002/gcc.70061","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>The molecular and histological characteristics of primary duodenal adenocarcinoma (DA) have been poorly described, which hampers the development of new treatment options. This study aimed to characterize the landscape of chromosomal copy number aberrations (CNAs), microsatellite instability status, and tumor–stroma content, and their association with clinicopathological characteristics of patients with DA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>DNA was extracted from tumor tissues of patients who underwent a primary surgical resection for DA in a single center (2000–2019). Shallow whole genome sequencing (sWGS) was performed to identify chromosomal CNAs and the genomic instability index (GII), for which 25% of the genome was altered, was used to classify tumors as CNA<sup>low</sup> or CNA<sup>high</sup>. A PCR-based assay was performed to classify tumors as microsatellite stable (MSS) or instable (MSI). Immunohistochemistry and digital image analysis were performed to determine the tumor–stroma content, for which 50% stroma content was used to classify tumors as stroma<sup>low</sup> or stroma<sup>high</sup>.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 74 patients with resected DA, sWGS identified 39 (52.7%) CNA<sup>low</sup> and 35 (47.3%) CNA<sup>high</sup> tumors. Overall, 16 (21.6%) DAs were MSI. All MSI tumors were CNA<sup>low</sup>. The tumor–stroma content was low in 51 (68.9%) and high in 23 (31.1%) of DAs. CNA status was most predictive for 5-year overall survival: 45.5% for patients with CNA<sup>low</sup> compared to 31.0% for patients with CNA<sup>high</sup> DA (HR 2.20, 95% CI 1.12–4.30, <i>p</i> = 0.02).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>About half of resected DAs had CNA<sup>low</sup>, which was associated with the most favorable prognosis. Subgrouping of DA could be used for patient stratification in future trials testing novel therapies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12700,"journal":{"name":"Genes, Chromosomes & Cancer","volume":"64 7","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/gcc.70061","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144606684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
YAP1::KMT2A-Rearranged Sarcoma: Report of a New Case With Unusual Morphology and Immunohistochemical Features YAP1:: kmt2a重排肉瘤:新病例报告,具有异常的形态和免疫组织化学特征
IF 3.1 2区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-07-11 DOI: 10.1002/gcc.70059
Caterina Fumagalli, Ruth Orellana, Sílvia Bagué, Malena Ferré, Allan Gonzalez, Lluis Catasús, Jaume Llauger, Ana Peiró, Paul Zamora Alarcón, Katarina Majercakova, Raúl Terés, Marie Karanian-Philippe, Franck Tirode, Cristina R. Antonescu

Recurrent KMT2A and YAP1 related fusions have recently been reported in various mesenchymal neoplasms of different histogenesis. First, YAP1::KMT2A fusions have been described in a subset of MUC4-negative sclerosing epithelioid fibrosarcomas (SEF), while VIM::KMT2A fusions in a handful of cases associated with an undifferentiated spindle cell phenotype lacking stromal hyalinization. On the other hand, YAP1 gene rearrangements have been reported in a wide spectrum of sarcomas, including vascular neoplasms such as epithelioid hemangioendothelioma (EHE). Despite these molecular advances, occasional challenges in classification may occur even if the pathognomonic fusion is identified. In this study, we report such a case of a soft tissue sarcoma displaying an unusual morphology and immunoprofile, which remained unclassified even after a YAP1::KMT2A fusion was detected. The lesion occurred in the left leg of a 65-year-old female and microscopically closely resembled a SEF, with epithelioid morphology organized in cords, nests, and sheets in a heavy hyalinized background. Focally, the cells showed cytoplasmic vacuoles with eosinophilic material, reminiscent of the “blisters cells” seen in EHE. Moreover, by immunohistochemistry (IHC), the tumor showed diffuse reactivity for vascular markers, including ERG, CD31, CD34, and D2-40, as well as for TFE3, while being negative for MUC4, CAMTA1, smooth-muscle actin, desmin, S100 and keratins. Targeted RNA sequencing revealed a YAP1::KMT2A fusion. Based on this molecular result and the conflicting morphologic and IHC findings, a definitive distinction between a MUC4-negative SEF and an EHE could not been established. To further subclassify the lesion, subsequent clustering analysis using RNAseq signature was performed against a vast group of sarcoma types on the same array. Results showed that the tumor was in close proximity to the SEF group, admixed together with the other YAP1::KMT2A MUC4 negative SEF sarcomas. This case is highly instructive, as it shows another application of RNA sequencing in clinical practice when discordant or uncertain results between pathologic findings and fusion type may occur. Indeed, RNAseq signature could help, in this context, to better classify the tumor as a YAP1::KMT2A sarcoma instead of a vascular tumor. Larger series are needed to evaluate the pathogenesis of these tumors and the relevance of vascular markers expression.

KMT2A和YAP1相关的复发融合最近在各种不同组织发生的间质肿瘤中被报道。首先,YAP1::KMT2A融合在muc4阴性硬化上皮样纤维肉瘤(SEF)的一个亚群中被描述,而VIM::KMT2A融合在少数与未分化梭形细胞表型缺乏间质透明化相关的病例中被描述。另一方面,YAP1基因重排已在广泛的肉瘤中被报道,包括血管肿瘤,如上皮样血管内皮瘤(EHE)。尽管有这些分子上的进步,但即使确定了病型融合,分类上偶尔也会出现挑战。在本研究中,我们报告了一例软组织肉瘤,表现出异常的形态和免疫谱,即使在检测到YAP1::KMT2A融合后仍未分类。病变发生在一名65岁女性的左腿,显微镜下与SEF非常相似,在重透明背景下,上皮样形态呈索状、巢状和片状。局部可见嗜酸性物质的细胞质空泡,与EHE中所见的“水泡细胞”相似。此外,通过免疫组化(IHC),肿瘤对血管标志物(包括ERG、CD31、CD34和D2-40)以及TFE3表现出弥漫性反应性,而MUC4、CAMTA1、平滑肌肌动蛋白、desmin、S100和角蛋白均呈阴性。靶向RNA测序显示YAP1::KMT2A融合。基于这一分子结果以及相互矛盾的形态学和免疫组化结果,muc4阴性SEF和EHE之间的明确区别无法确定。为了进一步对病变进行亚分类,随后使用RNAseq特征对同一阵列上的大量肉瘤类型进行聚类分析。结果表明,该肿瘤与其他YAP1::KMT2A MUC4阴性SEF肉瘤混在一起,与SEF组接近。本病例具有很高的指导意义,因为它显示了RNA测序在临床实践中的另一种应用,当病理结果与融合类型之间可能出现不一致或不确定的结果时。事实上,在这种情况下,RNAseq标记可以帮助更好地将肿瘤分类为YAP1::KMT2A肉瘤而不是血管肿瘤。需要更大的系列来评估这些肿瘤的发病机制和血管标志物表达的相关性。
{"title":"YAP1::KMT2A-Rearranged Sarcoma: Report of a New Case With Unusual Morphology and Immunohistochemical Features","authors":"Caterina Fumagalli,&nbsp;Ruth Orellana,&nbsp;Sílvia Bagué,&nbsp;Malena Ferré,&nbsp;Allan Gonzalez,&nbsp;Lluis Catasús,&nbsp;Jaume Llauger,&nbsp;Ana Peiró,&nbsp;Paul Zamora Alarcón,&nbsp;Katarina Majercakova,&nbsp;Raúl Terés,&nbsp;Marie Karanian-Philippe,&nbsp;Franck Tirode,&nbsp;Cristina R. Antonescu","doi":"10.1002/gcc.70059","DOIUrl":"https://doi.org/10.1002/gcc.70059","url":null,"abstract":"<p>Recurrent <i>KMT2A</i> and <i>YAP1</i> related fusions have recently been reported in various mesenchymal neoplasms of different histogenesis. First, <i>YAP1::KMT2A</i> fusions have been described in a subset of MUC4-negative sclerosing epithelioid fibrosarcomas (SEF), while <i>VIM::KMT2A</i> fusions in a handful of cases associated with an undifferentiated spindle cell phenotype lacking stromal hyalinization. On the other hand, <i>YAP1</i> gene rearrangements have been reported in a wide spectrum of sarcomas, including vascular neoplasms such as epithelioid hemangioendothelioma (EHE). Despite these molecular advances, occasional challenges in classification may occur even if the pathognomonic fusion is identified. In this study, we report such a case of a soft tissue sarcoma displaying an unusual morphology and immunoprofile, which remained unclassified even after a <i>YAP1::KMT2A</i> fusion was detected. The lesion occurred in the left leg of a 65-year-old female and microscopically closely resembled a SEF, with epithelioid morphology organized in cords, nests, and sheets in a heavy hyalinized background. Focally, the cells showed cytoplasmic vacuoles with eosinophilic material, reminiscent of the “blisters cells” seen in EHE. Moreover, by immunohistochemistry (IHC), the tumor showed diffuse reactivity for vascular markers, including ERG, CD31, CD34, and D2-40, as well as for TFE3, while being negative for MUC4, CAMTA1, smooth-muscle actin, desmin, S100 and keratins. Targeted RNA sequencing revealed a <i>YAP1::KMT2A</i> fusion. Based on this molecular result and the conflicting morphologic and IHC findings, a definitive distinction between a MUC4-negative SEF and an EHE could not been established. To further subclassify the lesion, subsequent clustering analysis using RNAseq signature was performed against a vast group of sarcoma types on the same array. Results showed that the tumor was in close proximity to the SEF group, admixed together with the other <i>YAP1::KMT2A</i> MUC4 negative SEF sarcomas. This case is highly instructive, as it shows another application of RNA sequencing in clinical practice when discordant or uncertain results between pathologic findings and fusion type may occur. Indeed, RNAseq signature could help, in this context, to better classify the tumor as a <i>YAP1::KMT2A</i> sarcoma instead of a vascular tumor. Larger series are needed to evaluate the pathogenesis of these tumors and the relevance of vascular markers expression.</p>","PeriodicalId":12700,"journal":{"name":"Genes, Chromosomes & Cancer","volume":"64 7","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/gcc.70059","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144606683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to “EWSR1::SSX1 Fusion-Driven Synovial Sarcoma: A Case Presentation and Review of the Literature” 更正“EWSR1::SSX1融合驱动滑膜肉瘤:一例报告和文献回顾”
IF 3.1 2区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-07-09 DOI: 10.1002/gcc.70065

J. Vega-Gonzalez, J. A. C. Toro, E. L. García, G. Marquina, M. d. l. T. Serrano, A. M. C. Gallardo, R. B. Giménez, D. H. Martínez, A. G. Egido, L. A. García, L. Nielsen, J. C. Plaza, and L. O. Medina, “EWSR1::SSX1 Fusion-Driven Synovial Sarcoma: A Case Presentation and Review of the Literature,” Genes Chromosomes Cancer 64 (2025): e70048, https://doi.org/10.1002/gcc.70048.

This article was originally published with the incorrect article category of “Review Article.” The correct category is Brief Report. This has been corrected in the online version of the article.

We apologize for this error.

J. Vega-Gonzalez, J. A. C. Toro, E. l. García, G. Marquina, M. d. T. Serrano, A. M. C. Gallardo, R. B. gimsamnez, d. H. Martínez, A. G. Egido, l. A. García, l. Nielsen, J. C. Plaza和l. O. Medina,“EWSR1::SSX1融合驱动滑膜肉瘤:一个病例介绍和文献回顾”,基因染色体癌症64 (2025):e70048, https://doi.org/10.1002/gcc.70048.This文章最初发表在错误的“综述文章”的文章分类中。正确的分类是简要报告。这在文章的在线版本中已被更正。我们为这个错误道歉。
{"title":"Correction to “EWSR1::SSX1 Fusion-Driven Synovial Sarcoma: A Case Presentation and Review of the Literature”","authors":"","doi":"10.1002/gcc.70065","DOIUrl":"https://doi.org/10.1002/gcc.70065","url":null,"abstract":"<p>J. Vega-Gonzalez, J. A. C. Toro, E. L. García, G. Marquina, M. d. l. T. Serrano, A. M. C. Gallardo, R. B. Giménez, D. H. Martínez, A. G. Egido, L. A. García, L. Nielsen, J. C. Plaza, and L. O. Medina, “EWSR1::SSX1 Fusion-Driven Synovial Sarcoma: A Case Presentation and Review of the Literature,” <i>Genes Chromosomes Cancer</i> 64 (2025): e70048, https://doi.org/10.1002/gcc.70048.</p><p>This article was originally published with the incorrect article category of “Review Article.” The correct category is Brief Report. This has been corrected in the online version of the article.</p><p>We apologize for this error.</p>","PeriodicalId":12700,"journal":{"name":"Genes, Chromosomes & Cancer","volume":"64 7","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/gcc.70065","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144589643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Genes, Chromosomes & Cancer
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1